Interventions supporting long term adherence and decreasing cardiovascular events after myocardial infarction (ISLAND): pragmatic randomised controlled trial

Cardiovascular Risk and DiseasesMyocardial Infarction

Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial

Lancet.

Näslund U, Ng N, Lundgren A, Fhärm E, Grönlund C, Johansson H, Lindahl B, Lindahl B, Lindvall K, Nilsson SK, Nordin M, Nordin S, Nyman E, Rocklöv J, Vanoli D, Weinehall L, Wennberg P, Wester P, Norberg M; VIPVIZA trial group

doi: 10.1016/S0140-

Myocardial Infarction

16-year follow-up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) trial: primary percutaneous coronary intervention vs. fibrinolysis in ST-segment elevation myocardial infarction

Eur Heart J.

Thrane PG, Kristensen SD, Olesen KKW, Mortensen LS, Bøtker HE, Thuesen L, Hansen HS, Abildgaard U, Engstrøm T, Andersen HR, Maeng M

doi: 10.1093/eurheartj/ehz595.

COMMENTED

Hypertension

A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial

Lancet.

Schwalm JD, McCready T, Lopez-Jaramillo P, Yusoff K, Attaran A, Lamelas P, Camacho PA, Majid F, Bangdiwala SI, Thabane L, Islam S, McKee M, Yusuf S

doi: 10.1016/S0140-

Myocardial Infarction

Meta-analysis of short- and long-term efficacy of mononuclear cell transplantation in patients with myocardial infarction

Am Heart J.

Yang D, O'Brien CG, Ikeda G, Traverse JH, Taylor DA, Henry TD, Bolli R, Yang PC

doi: 10.1016/j.ahj.2019.09.005.

Myocardial Infarction

Fast manual long-axis strain assessment provides optimized cardiovascular event prediction following myocardial infarction

Eur Heart J Cardiovasc Imaging.

Schuster A, Backhaus SJ, Stiermaier T, Kowallick JT, Stulle A, Koschalka A, Lotz J, Kutty S, Bigalke B, Gutberlet M, Hasenfuß G, Thiele H, Eitel I

doi: 10.1093/ehjci/jez077.

Cardiovascular Risk and Diseases

Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial

Lancet.

Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, Ostovaneh MR, Nateghi A, Majed M, Navabakhsh B, Merat S, Pourshams A, Nalini M, Malekzadeh F, Sadeghi M, Mohammadifard N, Sarrafzadegan N, Naemi-Tabiei M, Fazel A, Brennan P, Etemadi A, Boffetta P, Thomas N, Marshall T, Cheng KK, Malekzadeh R

doi: 10.1016/S0140-6736(19)31791-X.

Cardiovascular Risk and DiseasesMyocardial InfarctionThrombosis and Stroke

Effect of Baseline Nutritional Status on Long-term Multivitamin Use and Cardiovascular Disease Risk: A Secondary Analysis of the Physicians' Health Study II Randomized Clinical Trial

JAMA Cardiol.

Rautiainen S, Gaziano JM, Christen WG, Bubes V, Kotler G, Glynn RJ, Manson JE, Buring JE, Sesso HD

doi: 10.1001/jamacardio.

Myocardial InfarctionTherapy and Intervention

Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial

BMJ.

Kedhi E, Fabris E, van der Ent M, Buszman P, von Birgelen C, Roolvink V, Zurakowski A, Schotborgh CE, Hoorntje JCA, Eek CH, Cook S, Togni M, Meuwissen M, van Royen N, van Vliet R, Wedel H, Delewi R, Zijlstra F

doi: 10.1136/bmj.k3793.

RECOMMENDED

Cardiovascular Risk and DiseasesMyocardial InfarctionThrombosis and Stroke

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial

Lancet.

Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, Howard G, Pearson TA, Rothwell PM, Ruilope LM, Tendera M, Tognoni G, ARRIVE Executive Committee

doi: 10.1016/S0140-

Related content

Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial

16-year follow-up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) trial: primary percutaneous coronary intervention vs. fibrinolysis in ST-segment elevation myocardial infarction

A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial

Meta-analysis of short- and long-term efficacy of mononuclear cell transplantation in patients with myocardial infarction

Fast manual long-axis strain assessment provides optimized cardiovascular event prediction following myocardial infarction

Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial

Effect of Baseline Nutritional Status on Long-term Multivitamin Use and Cardiovascular Disease Risk: A Secondary Analysis of the Physicians' Health Study II Randomized Clinical Trial

Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial